← All trials
NCT04152486
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2019
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 500000
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- Janssen Pharmaceutica NVCollaborator
- University of LondonOverall official - principal investigator
- EpicentreCollaborator
- Public Health EnglandCollaborator
- Medecins Sans FrontieresCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
- Government of the Democratic Republic of the CongoCollaborator
- Government of the Democratic Republic of the CongoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.